The first patient has been dosed in a phase 1/2a clinical trial of AXT107 to evaluate the safety and bioactivity of the therapy in patients with diabetic macular edema, according to a press release from AsclepiX Therapeutics.
CONGO, an open-label, dose-escalating, 48-week trial, will evaluate a single intravitreal injection of AXT107 at a low dose of 0.1 mg, a mid-dose of 0.25 mg or a high dose of 0.5 mg in approximately 18 patients.
An investigational new drug application for AXT107 was cleared by the FDA in December for the treatment of retinal diseases such as DME, wet age-related macular
Uncategorized